PBMs should make 100% of their revenue from fees paid directly by their clients. This alignment of financial interests is essential to managing costs.
Coverage should be based on lowest net cost and value, not on rebate maximization or optimizing the profits of the PBM-owned pharmacy.
Full visibility of performance metrics is a critical foundation to holding the PBM accountable.
Fully aligned, value-based, transparent benefits are possible – for PBMs willing to use them, and for employers that insist on them.
Discover how EpiphanyRx is providing significant, ongoing savings for our clients in a way that no one else does.
We replace spread pricing, rebate retention and pharmacy ownership with an aligned, transparent business model focused on the lowest net cost and overall value for our clients.
Biosimilars are a hot topic in the pharmacy industry right now. Wondering what all the buzz is about? In this Fast Five, we asked our clinical experts, Janelle Sheen and Imke Scheepers, to share the basics about biosimilars as well as some key insights on this topic.
Our Vice President of Sales, Jonathan Har-Even, shares his outlook on the industry and where we need to go next. He discusses 5 ways the PBM industry can continue to improve and promote better healthcare for all, including a 5-year plan that uses lowest net cost as a foundation and builds out a platform for payors, members, and pharmacists.
Check out this insightful article published in JMCP on these challenges and the implications for plan sponsors working for a sustainable drug benefit.
Does your PBM provide transparent contracts and reporting? It is time to move PBM business intelligence out of the dark ages. This white paper is the third in a series dedicated to exploring best practices to help employers understand the challenges and opportunities in building a sustainable specialty drug benefit.
Is your PBM applying rigorous clinical criteria to effectively identify and remove waste in your specialty drug benefit? Learn how misaligned coverage models and weak clinical criteria are working against plan sponsors. This white paper is the second of three dedicated to exploring best practices to help employers understand the challenges and opportunities in building a sustainable specialty drug benefit.
Are your PBM's financial interests fully aligned with yours? Learn more about the inherent financial conflicts found in traditional PBM business models. This white paper is the first of three dedicated to exploring best practices to help employers understand the challenges and opportunities in building a sustainable specialty drug benefit.
Update your browser to view this website correctly. Update my browser now